Reporte zur Charge FJU989

Symptomtext

Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 77-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 05Mar2021 as dose 1, single (Lot number: EN61996130121), in left arm, on 26Mar2021 as dose 2, single (Lot number: EP75346130121), in left arm, on 21Oct2021 as dose 3 (booster), single (Lot number: FF2588), in left arm and on 19May2022 as dose 4 (booster), single (Lot number: FJU989) at the age of 77 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypothyroidism" (unspecified if ongoing); "known allergies Sulfa" (unspecified if ongoing); "gerd" (unspecified if ongoing); "General allergies" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Cipro, reaction(s): "known allergies cipro". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset May2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19. The patient took Anti-viral drug Paxlovid from 31May2022 to 07Jun2022 for COVID 19 treatment. No follow-up attempts are possible. No further information is expected.